News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Catalent Pharma Solutions Enters Into Commercial Supply Agreement With VIVUS, Inc. (VVUS) for Qsymia™ Once-Daily Combination-Extended-Release Capsules


10/1/2012 10:16:36 AM

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions announced that it has entered into a Supply Agreement with VIVUS, Inc. to supply Qsymia™ capsules, a proprietary combination phentermine and extended-release topiramate. Utilizing its unique drug delivery capabilities, Catalent partnered with VIVUS during the development of Qsymia, including pre-formulation and formulation, clinical supply and validation.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES